Manufacturer of Paracetamol Tablets in India
- Suncare Formulations Pvt Ltd
- Mar 5, 2024
- 2 min read
The pharmaceutical sector in India is a robust industry, with the country catering to a significant portion of the global demand for generic drugs. Paracetamol is one of the most widely used analgesics and antipyretics across the globe. The Indian paracetamol market has witnessed substantial growth, thanks to its widespread use in battling fever, pain, and symptoms of cold and flu. As of the latest reports, the market size of paracetamol in India is expected to expand at a Compound Annual Growth Rate (CAGR) of over 5% in the next five years, underscoring the increasing demand and the vital role of Indian manufacturers in meeting global healthcare needs.

Products Available
The variety of paracetamol formulations produced in India caters to diverse needs and preferences. These include:
Standard Tablets: The classic, most commonly used form, available in strengths of 500mg and 650mg.
Pediatric Suspension: A liquid form of paracetamol designed for children, with a pleasant flavour to ease administration.
Combination Products: Paracetamol is often combined with other active ingredients to target specific symptoms, such as cold and cough formulas.
We have the following strengths in paracetamol readily available:
We offer products of the highest quality at the most optimum prices. We have over 30 years of experience in manufacturing with two dedicated plants for pharmaceuticals and nutraceuticals. At Suncare, we understand that every business has different needs and capabilities. Our client-first approach has always allowed us to stay above the competition
Apart from the single-strength composition we also offer Paracetamol in combination with other APIs such as:
Apart from these, if you are interested in customizing formulations for your product, we will be glad to be your partner in the journey. We have an in-house formulation development team that will assist you in your journey from development to finished product.




Comments